Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 4, 2025
Reporting Period: As of March 4, 2025
Business Context: The filing addresses the termination of a specific prospectus supplement related to an "at-the-market" (ATM) equity offering program.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial figures disclosed relate to the ATM offering program:
- ATM Offering Capacity: Up to $6,500,000 (aggregate offering price).
- Shares Sold to Date: 230,068 shares.
- Aggregate Proceeds Received: $292,790.
Note: The filing text does not provide clear values for current debt, liquidity, or operating margins.
Material Changes
The primary material event reported is the termination of the ATM Prospectus Supplement dated December 6, 2022. Consequently:
- The Company will not make any further sales of common stock under the ATM Offering unless and until a new prospectus or prospectus supplement is filed.
- The underlying Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. remains in full force and effect, despite the termination of the specific prospectus supplement.
Guidance, Outlook, and Risks
Management Commentary: The filing is a procedural notification regarding the status of the equity offering program. No forward-looking guidance, outlook, or strategic commentary is provided in this document.
Risks and Contingencies: The termination of the prospectus supplement restricts the Company's ability to raise capital through this specific ATM mechanism until a new filing is completed. No other risks or contingencies are detailed in this report.
Key Facts for Investor Verification
- Verify the status of the underlying Sales Agreement with Cantor Fitzgerald & Co. to confirm if a new prospectus supplement is planned.
- Confirm the Company's current cash position and liquidity needs, as the ATM facility is currently inactive for new sales.
- Review recent 10-Q or 10-K filings for comprehensive financial performance data, as this 8-K contains no operational metrics.
- Note that only approximately $292,790 has been raised against the $6.5 million authorized capacity under the terminated supplement.